SanBio Company Limited (SNBIF) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Tokyo, 日本. 現CEOは Keita Mori.
SNBIF を有する IPO日 2015-10-12, 29 名の正社員, に上場 Other OTC, 時価総額 $1.28B.
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
